GLP-1 Drugs Linked to Lower Cancer Metastasis Risk in ASCO Study

New observational data presented at ASCO 2026 explores a potential link between GLP-1 drugs and cancer progression.

New Observational Data Presented at ASCO 2026

A large real-world analysis presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting suggests a potential association between GLP-1 receptor agonist (GLP-1RA) use and reduced progression to metastatic cancer in several obesity-related tumor types. The findings, while preliminary and observational in nature, represent some of the first large-scale data exploring this association across multiple cancer types simultaneously.

It is important to note that the study has not yet been published in a peer-reviewed journal, and experts have emphasized that observational findings cannot establish a cause-and-effect relationship. Further prospective clinical trials would be needed to validate these results.

What the Study Found

According to data presented in Abstract 3510 at ASCO, researchers analyzed records from over 10,000 patients with stage I–III cancer using the TriNetX Global Health Research Network. Patients who initiated GLP-1RA therapy after their cancer diagnosis were propensity-matched 1:1 against a control group taking DPP-4 inhibitors (gliptins), accounting for demographics, BMI, smoking status, comorbidities, screening frequency, and oncologic treatments.

The study examined seven obesity-related cancers and reported the following associations with reduced progression to stage IV disease among GLP-1RA users compared to controls:

• Non-small cell lung cancer (NSCLC): An observed 50% lower risk of metastatic progression
• Breast adenocarcinoma: An observed 43% lower risk
• Hepatocellular carcinoma (liver cancer): An observed 38% lower risk
• Colorectal adenocarcinoma: An observed 31% lower risk

According to the researchers, three additional cancer types — prostate, renal cell, and pancreatic adenocarcinoma — showed numerically fewer metastatic events in the GLP-1RA group, but these differences did not reach statistical significance.

Exploring a Potential Biological Mechanism

To investigate a possible biological basis for the observed association, the research team utilized data from The Cancer Genome Atlas (TCGA). According to their analysis, high expression of the GLP-1 receptor within tumors was associated with a 33% lower risk of death across the seven tumor types studied. The association appeared particularly notable in breast cancer, where high GLP-1 receptor expression was linked to a 45% reduction in mortality risk, according to the researchers.

Commentary from Dr. Monica Avila of the Moffitt Cancer Center, as reported by ASCO, noted that while the mechanistic data is intriguing, it remains unclear whether GLP-1 receptor signaling directly influences tumor biology or whether the observed associations reflect other factors such as improved metabolic health or weight management in GLP-1RA users. Those interested in learning more about semaglutide treatment programs should consult with a healthcare provider about their individual circumstances.

Safety Observations and Limitations

According to the study data presented at ASCO, adverse event rates — including instances of pancreatitis and stomach inflammation — were comparable between the GLP-1RA and control groups. No significant new safety signals were reported.

However, oncology experts have highlighted several important limitations that should be considered when interpreting these findings:

• The study is observational and retrospective, meaning it can identify associations but cannot prove that GLP-1 drugs caused the reduced metastasis rates
• Propensity matching, while rigorous, cannot fully eliminate confounding variables that may influence outcomes
• The control group used DPP-4 inhibitors, which may themselves have biological effects on cancer, potentially complicating the comparison
• The findings have not yet undergone peer review and full publication

What This May Mean Going Forward

Researchers and oncology experts have called for prospective, randomized controlled trials to further evaluate whether GLP-1 receptor agonists may play a role in cancer management. According to ASCO, these preliminary findings add to a growing body of observational research suggesting that GLP-1RAs may have effects beyond metabolic health, though no conclusions can be drawn until more rigorous evidence is available.

Patients currently taking GLP-1 medications for weight management or diabetes should not change their treatment plans based on these preliminary findings. Anyone with questions about their cancer risk or treatment should speak directly with their oncologist or healthcare provider.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.